title: Cholesterol gallstone formation in man and potential treatments of the gallbladder motility defect.
abstract: Cholelithiasis affects 10-15% of the adult population in Western society, and about 75% of gallstones are of cholesterol type. Hepatic hypersecretion of cholesterol with the formation of instable cholesterol-rich vesicles in bile, an imbalance between nucleation-inhibiting and nucleation-promoting proteins with further aggregation of cholesterol crystals in a gallbladder with a motility defect (stasis), all play a role in the pathogenesis of cholesterol gallstones. Experimental animal models suggest that gallstone formation can be prevented by improving gallbladder emptying. Thus, a better understanding of the causes underlying the impaired gallbladder motor function in patients with gallstones might lead to the selection of therapeutic approaches for those individuals who are at increased risk for the formation or recurrence of gallstones. The present article focuses on current concepts and theories on the pathogenesis of cholesterol gallstones with emphasis on the gallbladder motility defect. Several treatment strategies for the correction of gallbladder hypomotility are also discussed.
authors.affiliation: Dept. of Gastroenterology, University Hospital Utrecht, The Netherlands.
authors.forename: P
authors.initials: P
authors.lastname: Portincasa
authors.forename: M F
authors.initials: MF
authors.lastname: Stolk
authors.forename: K J
authors.initials: KJ
authors.lastname: van Erpecum
authors.forename: G
authors.initials: G
authors.lastname: Palasciano
authors.forename: G P
authors.initials: GP
authors.lastname: van Berge-Henegouwen
mesh_terms: D000328:Adult; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002769:Cholelithiasis / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D002784:Cholesterol / Q000737:chemistry / Q000378:metabolism*; D020117:Cisapride; D003460:Crystallization; D005260:Female; D016473:Gallbladder Emptying / Q000502:physiology*; D006801:Humans; D015994:Incidence; D018942:Macrolides; D008297:Male; D010277:Parasympathomimetics / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents; D018942:Macrolides; D010277:Parasympathomimetics; D010880:Piperidines; D002784:Cholesterol; D020117:Cisapride